Brief: Bioinvent: Promising Initial Efficacy Data From Triple Combination Arm Of BI-1206, Rituximab And Calquence
08/01/2025 07:00
Jan 8 (Reuters) - BioInvent International AB BINV.ST :
* TREATMENT HAS BEEN WELL-TOLERATED WITH NO SAFETY OR
TOLERABILITY
CONCERNS
* STUDY NOW EXPANDING TO ADDITIONAL CLINICAL INVESTIGATIONAL
SITES
AND PATIENT ENROLLMENT ON TRACK WITH FURTHER PHASE 2A RESULTS
EXPECTED BY MID-2025
Source text: ID:nMFNbB0kT2
Further company coverage: BINV.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))